Personalize My Medicine
Personalize My Medicine works to help bridge the information gap between the explosion in medical innovations and the researchers, doctors, and patients who want to apply this information to their work and life, thus placing patients at the center of medical advancements. The goal of Personalize My Medicine is to solve this problem by creating a patient-centered medicine approach, in which patients have better access to innovations and actively participate in making them available.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Patient Worthy Posts on Rare Disease and Medication
Simple Daily Habits to Boost Your Whole-Body Health and Well-Being
Editor’s Note: Patient Worthy is honored to share this article, originally submitted by Camille Johnson. For chronic disease patients living with rare conditions and long-term
Extended Acoramidis Data Show Durable Survival Advantage in ATTR-CM
As reported on Cardiovascular Business, new long-term findings presented at the American College of Cardiology (ACC) 2026 meeting provide compelling evidence that early and continuous
New Study Reports How Individual Areas of the Brain Age
A pivotal study recently published in the journal Gero Science has revealed new insights into how individual brain regions age and why some are more
Optimized Dosing Delivers Enhanced Motor Benefits: FDA Approves High-Dose Spinraza Regimen for Spinal Muscular Atrophy
A decade of accumulated clinical experience with nusinersen has culminated in a significant regulatory advancement. According to Pharma Times Online, Biogen’s newly approved high-dose Spinraza
Ocular Therapeutix Reports Durable One-Year Outcomes for AXPAXLI in Wet AMD
As reported by Manila Times, Ocular Therapeutix has released additional one‑year results from its Phase 3 SOL‑1 trial evaluating AXPAXLI (formerly OTX‑TKI) for the treatment
Clinical and Regulatory Updates Highlight Momentum Across Biopharma
As reported on BioPharmaDive, several biopharmaceutical companies reported notable clinical and regulatory developments this week, with investor response reflecting growing confidence in both late‑stage pipelines
